Kenya Ophthalmic Drugs Market Analysis

Kenya Ophthalmic Drugs Market Analysis


$ 3999

Kenya ophthalmic drugs market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 – 2030. The key factors driving the growth of the global ophthalmic drugs market are the rise in the elderly population, the prevalence of eye diseases like glaucoma, cataracts, and macular degeneration, the surge in ophthalmic drug demand, and the increase in investment in R&D activities by different healthcare companies. The major key players in this market are Pfizer Inc., Alcon, Novartis AG, Bausch Health Companies Inc., Merck & Co., Inc., Regeneron Pharmaceuticals Inc., Allergan (AbbVie Inc.), Bayer AG, Genentech, Inc. (F. Hoffmann-La Roche Ltd), Nicox, Coherus Biosciences, Inc.

ID: IN10KEPH344 CATEGORY: Pharmaceuticals GEOGRAPHY: Kenya AUTHOR: Dr. Netal Patel

Buy Now

Kenya Ophthalmic Drugs Market Analysis Summary

Kenya Ophthalmic Drugs Market is valued at around $31.2 Mn in 2022 and is projected to reach $54.3 Mn by 2030, exhibiting a CAGR of 7.2% during the forecast period 2023-2030.

Ophthalmic disorders, sometimes known as eye diseases, are ailments that affect the eyes and the structures around them. These conditions can range from mild, temporary issues to severe, chronic disorders that can obstruct vision or result in visual loss. Ophthalmic diseases can affect anybody, including infants and the elderly, and can be caused by a variety of factors, including genetics, infections, trauma, or underlying medical conditions. Ophthalmic illnesses are treated with a variety of medications. These drugs are intended to treat various eye problems, and they can aid with symptom management, disease progression slowing, or healing promotion. A few classes of drugs that can be used in Ophthalmic disease conditions are anti-inflammatory drugs, anti-viral drugs, antibiotics, analgesics, anti-glaucoma drugs, and many more based on the type and severity of the condition. The key factors driving the growth of the global ophthalmic drugs market are the rise in the elderly population, the prevalence of eye diseases like glaucoma, cataracts, and macular degeneration, the surge in ophthalmic drug demand, and the increase in investment in R&D activities by different healthcare companies. The major key players in this market are Pfizer Inc., Alcon, Novartis AG, Bausch Health Companies Inc., Merck & Co., Inc., Regeneron Pharmaceuticals Inc., Allergan (AbbVie Inc.), Bayer AG, Genentech, Inc. (F. Hoffmann-La Roche Ltd), Nicox, Coherus Biosciences, Inc.

Market Dynamics

Market Growth Drivers

The incidence and prevalence of eye-related ailments are on the rise, and research and development on the creation of novel pharmaceuticals as well as the development of combination therapies are all driving the market's expansion. The primary reason for boosting market growth is the increased prevalence of eye-related ailments such as glaucoma, dry eye disease, and other eye-related disorders. Additionally, businesses' increased emphasis on R&D initiatives and expanding adoption of various business strategies, including mergers and acquisitions, collaborations, and partnerships, are anticipated to boost expansion in the market under study.

Market Restraints

Over the projected period, the expansion of the ophthalmic medicines market is anticipated to be constrained by the expiration of patent protection for popular medications used to treat eye illnesses and the absence of health insurance in developing nations.

Competitive Landscape

Key Players

  • Pfizer Inc.
  • Alcon
  • Novartis AG
  • Bausch Health Companies Inc.
  • Merck & Co., Inc.
  • Regeneron Pharmaceuticals Inc.
  • Allergan (AbbVie Inc.)
  • Bayer AG
  • Genentech, Inc. (F. Hoffmann-La Roche Ltd)
  • Nicox
  • Coherus Biosciences, Inc.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Kenya Ophthalmic Drugs Market Segmentation

By Indications

  • Dry Eye
  • Glaucoma
  • Infection/Inflammation/Allergy
  • Retinal Disorders
  • Wet Age-related Macular Degeneration
  • Dry Age-related Macular Degeneration
  • Diabetic Retinopathy
  • Others
  • Others

By Type

  • Prescription Drugs
  • Over-the-counter Drugs

By Distribution Channels

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Distribution Channels

  • Liquid Ophthalmic Drug Forms
  • Solid Ophthalmic Drug Forms
  • Semisolid Ophthalmic Drug Forms
  • Multicompartment Drug Delivery Systems
  • Other Ophthalmic Drug Forms

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 27 February 2024
Updated by: Bhanu Pratap Singh

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up